OASAS: Revisions to the Guidance on
Long-Acting (XR) Buprenorphine Injection

April 19, 2023

The Consolidated Appropriations Act of 2023 that was signed into law on December 29, 2022, enacted important changes in the treatment of opioid use disorder (OUD), including:

  • the elimination of Drug Enforcement Agency (DEA) X-waiver requirement to prescribe buprenorphine
  • an increase in the number of days from 14 days to 45 days before which certain controlled medications, such as long-acting (XR) injectable buprenorphine, must be administered after the pharmacy has delivered the medication to the prescribing healthcare professional.

The Guidance on Long-Acting (XR) Buprenorphine Injection that was issued in May 2022 has been revised to reflect these changes.  The Guidance can be found at: https://oasas.ny.gov/oasas-xr-buprenorphine-guidance

Please share this email with staff who prescribe medications.

Questions about the Guidance can be sent to the Addiction Medicine Mailbox at AddictionMedicine@oasas.ny.gov

Communications Department

NYS Office of Addiction Services and Supports (OASAS)